Streetbeat News

Analyst Ratings

BNTX

Canaccord Genuity analyst Bill Maughan maintains a Buy rating on BioNTech (NASDAQ:BNTX) and raises the price target from $168 to $171.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 2:59 pm

BIIB

Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Biogen (NASDAQ:BIIB) but lowers the price target from $310 to $305.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 2:56 pm

MFC

RBC Capital analyst Darko Mihelic has maintained an Outperform rating on Manulife Financial (TSX:MFC) and increased the price target from C$34 to C$38.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 2:33 pm

DASH

Wells Fargo analyst Ken Gawrelski maintains an Equal-Weight rating on DoorDash (DASH) and lowers the price target from $105 to $100.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 2:11 pm

CGON

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on CG Oncology (NASDAQ:CGON) with an Overweight rating and a price target of $75.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 2:10 pm

PRLD

HC Wainwright & Co. analyst Robert Burns downgraded Prelude Therapeutics (PRLD) from Buy to Neutral and set a price target of $5. This adjustment reflects a change in the firm's outlook on PRLD's stock.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 2:03 pm

SQ

Seven analysts have recently updated their ratings on Block (NYSE:SQ), showing a mix of bullish and somewhat bullish sentiments with no bearish or indifferent stances. The average 12-month price target among analysts is $91.00, slightly down from the previous $92.67. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their response to Block's market performance and financial metrics. Block's financials indicate positive revenue growth but challenges in profitability and efficiency, with a net margin of -0.52% and ROE of -0.16%.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 2:01 pm